Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Algert Global LLC

Algert Global LLC cut its stake in Exelixis, Inc. (NASDAQ:EXEL) by 35.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 179,486 shares of the biotechnology company’s stock after selling 96,554 shares during the period. Algert Global LLC owned about 0.06% of Exelixis worth $5,977,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Invesco Ltd. raised its position in Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock valued at $132,376,000 after purchasing an additional 3,001,204 shares during the last quarter. Norges Bank purchased a new stake in shares of Exelixis in the fourth quarter valued at about $94,867,000. Caisse DE Depot ET Placement DU Quebec boosted its stake in shares of Exelixis by 330.4% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,484,395 shares of the biotechnology company’s stock worth $82,730,000 after buying an additional 1,907,167 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in shares of Exelixis by 104.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock worth $105,208,000 after buying an additional 1,613,482 shares during the last quarter. Finally, AQR Capital Management LLC increased its position in Exelixis by 25.7% in the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company’s stock valued at $132,101,000 after acquiring an additional 810,857 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Guggenheim reiterated a “buy” rating and issued a $42.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Barclays boosted their price objective on shares of Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Wells Fargo & Company restated a “market outperform” rating on shares of Exelixis in a research note on Thursday, April 17th. Stephens reiterated an “equal weight” rating and set a $29.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Finally, Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $41.00 to $33.00 in a research report on Friday, January 24th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $37.59.

Exelixis Trading Up 0.6 %

Shares of EXEL opened at $39.84 on Tuesday. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.26. The stock has a market cap of $10.98 billion, a P/E ratio of 22.51, a PEG ratio of 1.13 and a beta of 0.25. The company has a 50-day moving average of $37.00 and a two-hundred day moving average of $35.20.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Activity

In other Exelixis news, EVP Dana Aftab sold 1,508 shares of Exelixis stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total value of $58,812.00. Following the completion of the sale, the executive vice president now owns 693,181 shares in the company, valued at $27,034,059. The trade was a 0.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bob Oliver sold 18,647 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the sale, the director now owns 33,514 shares of the company’s stock, valued at approximately $1,248,396.50. The trade was a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 141,851 shares of company stock worth $5,236,046 over the last three months. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.